Donald A. Guloien
Analyst · BMO Capital
Gabriel, I'll try and Steve might want to fill in. That blocking and tackling is stuff that we have been doing over the past 3 years, quite frankly. And we've raised the prices on a huge variety of products across the company, made others more capital efficient by product design changes and features and benefits and so on. And we have been cutting costs in the appropriate places, and we'll be doing more of that. That has happened. It's going to find its way into earnings. Though the challenge that we've had quite frankly is not generating the core earnings, right, because if you were to project -- go back to a question that Mario asked about the compound growth rate and earnings, if you took it from last year's very modest earnings to $4 billion, you'd get a very high number. Let's put it right out there. Frankly, the issues that have bedeviled us are a series of basis changes that have taken place over the past 4 years. And the impact of lowering interest rates on us, which caused us to reprice and change products, take more strain and have reserve hits. Absent those 2 things, the story in terms of the underlying is actually pretty positive. I will mention one other factor, and this is a good news and bad news story. The good news is we've achieved hedging 2 years ahead of plan. The bad news is, that has a cost. Hedging has a cost. So I think all shareholders should feel good that we have dramatically reduced the volatility of our earnings by being able to opportunistically hedge at the right times. But that hedging does have a cost, and that does reduce our core earnings. So the underlying growth in earnings is there, but it has been set back by the macroeconomic changes, the faster-than-expected hedging, which is a positive but does have a cost in the short term, not in the long term, and the basis changes that hopefully will reduce in size, if not eliminate.
Gabriel Dechaine - Crédit Suisse AG, Research Division: I appreciate that. And just the last one here. Also, I guess, maybe not so earnings-related but capital management. Is there any stuff here, your -- ideas you're toying around with now because a few of your peers in the U.S., especially the big -- well, they're not run-off books but they're legacy businesses, ways to enhance value or spin off capital sooner than expected from the VA book, for example? Some companies are playing around with an enhanced surrender options to their -- or offers to their policyholders, stuff like that. And then also on the Long-Term Care, I noticed that the repricing, you've got 41 states approved. You don't give a number anymore about how actual pricing approvals compare to your 40% targeted increase.